Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464034 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Criterium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
NCT01464034 is a Phase 1 study that was terminated before completion, run by Criterium. The registered enrollment target is 136 participants.
The verdict
NCT01464034, a Phase 1 study, was terminated before completion, sponsored by Criterium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2011-11 |
| Est. Completion | 2020-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464034
The ClinicalTrials.gov registry entry for NCT01464034 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Criterium, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01464034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464034 about?
NCT01464034 is a clinical study titled "A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.
What is the current status of trial NCT01464034?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2011-11. Estimated completion is 2020-07.
What interventions are being tested in trial NCT01464034?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01464034?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.